Effect of once-a-day fractionated total body irradiation on the risk of relapse after non-T-cell-depleted HLA-matched sibling transplantation.
OBJECTIVE
The aim of this study was to assess the impact of fractionated total body irradiation (F-TBI) on treatment-related mortality (TRM) and relapse in patients who received a non-T-cell-depleted allogeneic stem cell transplantation (ASCT) for hematological malignancies.


METHODS
Between March 2003 and December 2004, a total of 24 patients with HLA-identical sibling donors entered this study and received three doses of 3.33 Gy F-TBI separated by 24 h and cyclophosphamide or etoposide.


RESULTS
At a median follow-up of 37 months (range 29-47 months), 4 of the 24 patients (16.6%) died of TRM. Relapse occurred in 10 patients at a median of 9 months (range 2-18 months). Overall, 13 of 24 patients (54%) died. Relapse was the most common cause of death (9/13). The 2-year actuarial survival rate was 46% (+/-11%).


CONCLUSIONS
In our experience, ASCT conditioned with F-TBI was associated with low TRM but a high early relapse rate in patients with hematological malignancies.
Othman
Tarek Ben
TB
Centre National de Greffe de Moelle Osseuse, Rue Jebel Lakhdar, 1006, Bab Saadoun, Tunis, Tunisia.
Kochbati
Lotfi
L
Abdelkefi
Abderrahman
A
Ladeb
Saloua
S
Torjman
Lamia
L
Lakhal
Amel
A
Kammoun
Leila
L
Hentati
Dalenda
D
Besbes
Mounir
M
Abdeladhim
Abdeladhim Ben
AB
Maalej
Mongi
M
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007938:Leukemia / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D008297:Male; D012008:Recurrence; D035781:Siblings; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation / Q000009:adverse effects* / Q000379:methods
D006680:HLA Antigens